4.07
4.07 (0%)
As of Feb 14, 2025
Trevi Therapeutics, Inc. [TRVI]
Source:
Company Overview
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, chronic cough in patients with non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC.
| Country | United States |
| Headquarters | new haven, connecticut |
| Phone Number | (203) 304-2499 |
| Industry | manufacturing |
| CEO | Jennifer Good |
| Website | www.trevitherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-51.5 |
| Net Income | $-47.9 |
| Net Cash | $1.7 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -47.8% |
| Profit as % of Stockholder Equity | -48.1% |
Management Effectiveness
| Return on Equity | -48.1% |
| Return on Assets | -43.2% |
| Turnover Ratio | |
| EBITA | $-51.5 |
Balance Sheet and Cash Flow Measures
| Total Assets | $110.9 |
| Total Liabilities | $11.3 |
| Operating Cash Flow | $-38.3 |
| Investing Cash Flow | $-21.5 |
| Financing Cash Flow | $61.5 |
